Shire PLC's acceptance, as expected, of a £48.17 per share acquisition offer from determined pursuer Takeda Pharmaceutical Co. Ltd., paves the way for a roughly £46bn ($62.45bn) deal that will create a new force just inside the global pharma top 10, and also marks both the biggest ever M&A transaction by the Japanese pharma sector and the largest overseas buy-out in any sector in Japan.
The combined sales of the merged group are estimated to be around $30bn, based on recent annual sales, and Takeda's doggedness may well be explained by Shire being seen
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?